6WMC
 
 | |
7N3E
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C032 | | Descriptor: | C032 Fab Heavy Chain, C032 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.06 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3G
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C098 | | Descriptor: | C098 Fab Heavy Chain, C098 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.42 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3F
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C080 | | Descriptor: | C080 Fab Heavy Chain, C080 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3H
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C099 | | Descriptor: | C099 Fab Heavy Chain, C099 Fab Light Chain | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.26 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
7N3I
 | | Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C098 Fab heavy chain, C098 Fab light chain, ... | | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | | Deposit date: | 2021-06-01 | | Release date: | 2021-08-04 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.03 Å) | | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity, 54, 2021
|
|
5IWM
 | | 2.5A structure of GSK945237 with S.aureus DNA gyrase and DNA. | | Descriptor: | (1R)-1-[(4-{[(6,7-dihydro[1,4]dioxino[2,3-c]pyridazin-3-yl)methyl]amino}piperidin-1-yl)methyl]-9-fluoro-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one, DNA (5'-D(*AP*GP*CP*CP*GP*TP*AP*GP*GP*TP*TP*CP*AP*CP*CP*GP*CP*AP*CP*A)-3'), DNA (5'-D(*TP*GP*TP*GP*CP*GP*GP*TP*GP*AP*AP*CP*CP*TP*AP*CP*GP*GP*CP*T)-3'), ... | | Authors: | Bax, B.D, Miles, T.J. | | Deposit date: | 2016-03-22 | | Release date: | 2016-05-25 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.
Bioorg.Med.Chem.Lett., 26, 2016
|
|
6VDN
 | | HCV NS3/4A protease A156T mutant | | Descriptor: | GLYCEROL, Non-structural protein 4A, Serine protease NS3, ... | | Authors: | Timm, J, Schiffer, C.A. | | Deposit date: | 2019-12-27 | | Release date: | 2020-12-30 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.15 Å) | | Cite: | apo HCV protease A156T
To Be Published
|
|
6VDL
 | | HCV NS3/4A protease A156T mutant in complex with glecaprevir | | Descriptor: | (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17, 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide, GLYCEROL, ... | | Authors: | Timm, J, Schiffer, C.A. | | Deposit date: | 2019-12-27 | | Release date: | 2020-12-30 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.95 Å) | | Cite: | RAS at position 156 of HCV NS3/4A protease abolish inhibition by current HCV drugs
To Be Published
|
|
6VDM
 | | HCV NS3/4A protease A156T, D168E double mutant in complex with glecaprevir | | Descriptor: | (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17, 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide, GLYCEROL, ... | | Authors: | Timm, J, Schiffer, C.A. | | Deposit date: | 2019-12-27 | | Release date: | 2020-12-30 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | RAS at position 156 of HCV NS3/4A protease abolish inhibition by current HCV drugs
To Be Published
|
|
6VDO
 | |
8JBJ
 | | Crystal structure of anti-PVRIG Fab | | Descriptor: | antibody heavy chain, antibody light chain | | Authors: | Sun, J, Li, X.L, Song, J. | | Deposit date: | 2023-05-09 | | Release date: | 2023-06-21 | | Method: | X-RAY DIFFRACTION (1.61 Å) | | Cite: | Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity.
Mabs, 15, 2023
|
|
4JDO
 | | Secreted chlamydial protein pgp3, coiled-coil deletion | | Descriptor: | SODIUM ION, Virulence plasmid protein pGP3-D | | Authors: | Galaleldeen, A, Taylor, A.B, Chen, D, Holloway, S.P, Zhong, G, Hart, P.J. | | Deposit date: | 2013-02-25 | | Release date: | 2013-06-05 | | Last modified: | 2023-12-06 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Structure of the Chlamydia trachomatis immunodominant antigen Pgp3.
J.Biol.Chem., 288, 2013
|
|
4JDN
 | | Secreted Chlamydial Protein PGP3, C-terminal Domain | | Descriptor: | GLYCEROL, POTASSIUM ION, Virulence plasmid protein pGP3-D | | Authors: | Galaleldeen, A, Taylor, A.B, Chen, D, Holloway, S.P, Zhong, G, Hart, P.J. | | Deposit date: | 2013-02-25 | | Release date: | 2013-06-05 | | Last modified: | 2013-10-09 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Structure of the Chlamydia trachomatis immunodominant antigen Pgp3.
J.Biol.Chem., 288, 2013
|
|
4JDM
 | | Secreted Chlamydial Protein PGP3, full-length | | Descriptor: | Virulence plasmid protein pGP3-D | | Authors: | Galaleldeen, A, Taylor, A.B, Chen, D, Holloway, S.P, Zhong, G, Hart, P.J. | | Deposit date: | 2013-02-25 | | Release date: | 2013-06-05 | | Last modified: | 2013-10-09 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Structure of the Chlamydia trachomatis immunodominant antigen Pgp3.
J.Biol.Chem., 288, 2013
|
|
6F4D
 | |
4G3Y
 | | Crystal structure of TNF-alpha in complex with Infliximab Fab fragment | | Descriptor: | Tumor necrosis factor, infliximab Fab H, infliximab Fab L | | Authors: | Liang, S.Y, Dai, J.X, Guo, Y.J, Lou, Z.Y. | | Deposit date: | 2012-07-15 | | Release date: | 2013-03-27 | | Last modified: | 2013-08-07 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab
J.Biol.Chem., 288, 2013
|
|
7F65
 | | Bacetrial Cocaine Esterase with mutations T172R/G173Q/V116K/S117A/A51L, bound to benzoic acid | | Descriptor: | BENZOIC ACID, Cocaine esterase, SULFATE ION | | Authors: | Ouyang, P.F, Zhang, Y, Tong, J. | | Deposit date: | 2021-06-24 | | Release date: | 2021-09-15 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.202 Å) | | Cite: | Computational Design and Crystal Structure of a Highly Efficient Benzoylecgonine Hydrolase.
Angew.Chem.Int.Ed.Engl., 60, 2021
|
|
1QA5
 | |
5CH8
 | | Crystal structure of MDLA N225Q mutant form Penicillium cyclopium | | Descriptor: | CHLORIDE ION, GLYCEROL, Mono- and diacylglycerol lipase, ... | | Authors: | Xu, J, Xu, H, Hou, S, Liu, J. | | Deposit date: | 2015-07-10 | | Release date: | 2016-04-20 | | Last modified: | 2017-09-27 | | Method: | X-RAY DIFFRACTION (1.62 Å) | | Cite: | Lipase-Driven Epoxidation Is A Two-Stage Synergistic Process
ChemistrySelect, 4, 2016
|
|
3WLW
 | | Molecular Architecture of the ErbB2 Extracellular Domain Homodimer | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Antibody H Chain, ... | | Authors: | Hu, S, Lou, Z.Y, Guo, Y.J. | | Deposit date: | 2013-11-15 | | Release date: | 2015-05-27 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (3.088 Å) | | Cite: | Molecular architecture of the ErbB2 extracellular domain homodimer.
Oncotarget, 6, 2015
|
|
3WD5
 | | Crystal structure of TNFalpha in complex with Adalimumab Fab fragment | | Descriptor: | Adalimumab Heavy Chain, Adalimumab Light Chain, Tumor necrosis factor | | Authors: | Hu, S, Liang, S.Y, Guo, Y.J, Lou, Z.Y. | | Deposit date: | 2013-06-06 | | Release date: | 2013-08-14 | | Last modified: | 2015-07-01 | | Method: | X-RAY DIFFRACTION (3.101 Å) | | Cite: | Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view
J.Biol.Chem., 288, 2013
|
|
8HJT
 | | Crystal Structure of Intracellular B30.2 Domain of VpBTN3 and VpBTN2 in Complex with HMBPP | | Descriptor: | (2E)-4-hydroxy-3-methylbut-2-en-1-yl trihydrogen diphosphate, 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, Butyrophylin 3, ... | | Authors: | Yang, Y.Y, Shen, P.P, Li, X, Yi, S.M, Zhang, M.T, Huang, J.-W, Chen, C.-C, Guo, R.-T. | | Deposit date: | 2022-11-23 | | Release date: | 2023-09-13 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.91 Å) | | Cite: | Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V gamma 9V delta 2 T cells.
Nature, 621, 2023
|
|
4P08
 | | Engineered thermostable dimeric cocaine esterase | | Descriptor: | Cocaine esterase | | Authors: | Rodgers, D.W, Chow, K.-M, Fang, L, Zhan, C.-G. | | Deposit date: | 2014-02-20 | | Release date: | 2014-07-16 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (2.341 Å) | | Cite: | Rational design, preparation, and characterization of a therapeutic enzyme mutant with improved stability and function for cocaine detoxification.
Acs Chem.Biol., 9, 2014
|
|
2A0T
 | | NMR structure of the FHA1 domain of Rad53 in complex with a biological relevant phosphopeptide derived from Madt1 | | Descriptor: | Hypothetical 73.8 kDa protein in SAS3-SEC17 intergenic region, residues 301-310, Serine/threonine-protein kinase RAD53 | | Authors: | Mahajan, A, Yuan, C, Pike, B.L, Heierhorst, J, Chang, C.-F, Tsai, M.-D. | | Deposit date: | 2005-06-16 | | Release date: | 2005-11-08 | | Last modified: | 2022-03-09 | | Method: | SOLUTION NMR | | Cite: | FHA Domain-Ligand Interactions: Importance of Integrating Chemical and Biological Approaches
J.Am.Chem.Soc., 127, 2005
|
|
